|
1
|
Yang J, Li Y, Sun J, Zou H, Sun Y, Luo J, Xie Q, A R, Wang H, Li X, Wang K, Yang L, Ma T, Wu L, Sun X. An Osimertinib-Perfluorocarbon Nanoemulsion with Excellent Targeted Therapeutic Efficacy in Non-small Cell Lung Cancer: Achieving Intratracheal and Intravenous Administration. ACS NANO 2022; 16:12590-12605. [PMID: 35863049 DOI: 10.1021/acsnano.2c04159] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Low accumulation of anticancer drugs in tumors and serious systemic toxicity remain the main challenges to the clinical efficiency of pharmaceuticals. Pulmonary delivery of nanoscale-based drug delivery systems offered a strategy to increase antitumor activity with minimal adverse exposure. Herein, we report an osimertinib-loaded perfluoro-15-crown-5-ether (AZD9291-PFCE) nanoemulsion, through intratracheal and intravenous delivery, synergizes with 19F magnetic resonance imaging (19F MRI)-guided low-intensity focused ultrasound (LIFU) for lung cancer therapy. Pulmonary delivery of AZD9291-PFCE nanoemulsion in orthotopic lung carcinoma models achieves quick distribution of the nanoemulsion in lung tissues and tumors without short-term and long-term toxic effects. Furthermore, LIFU can trigger drug release from the AZD9291-PFCE nanoemulsion and specifically increases tumor vascular and tumor tissue permeability. 19F MRI was applied to quantify nanoemulsion accumulation in tumors in real time after LIFU irradiation. We validate the treatment effect of AZD9291-PFCE nanoemulsion in resected human lung cancer tissues, proving the translational potential to enhance clinical outcomes of lung cancer therapy. Thus, this work presents a promising pulmonary nanoemulsion delivery system of osimertinib (AZD9291) for targeted therapy of lung cancer without severe side effects.
Collapse
Affiliation(s)
- Jie Yang
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| | - Yingbo Li
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| | - Jiemei Sun
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| | - Hongyan Zou
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| | - Yige Sun
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| | - Jing Luo
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| | - Qian Xie
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| | - Rong A
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| | - Hongbin Wang
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| | - Xiaona Li
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| | - Kai Wang
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| | - Lili Yang
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| | - Teng Ma
- Shenzhen Key Laboratory of Ultrasound Imaging and Therapy, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 518055 Shenzhen, Guangdong, China
| | - Lina Wu
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| | - Xilin Sun
- NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Molecular Imaging Research Center (MIRC), Harbin Medical University, 150028 Harbin, Heilongjiang, China
- Department of Nuclear Medicine, the Fourth Hospital of Harbin Medical University, 150028 Harbin, Heilongjiang, China
| |
Collapse
|
|
3
|
Yang CF, Lin CH, Chiou SY, Yang YC, Tsao PC, Lee YS, Soong WJ, Jeng MJ. Intratracheal budesonide supplementation in addition to surfactant improves pulmonary outcome in surfactant-depleted newborn piglets. Pediatr Pulmonol 2013; 48:151-9. [PMID: 22489085 DOI: 10.1002/ppul.22564] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/08/2011] [Revised: 03/14/2012] [Accepted: 03/15/2012] [Indexed: 11/09/2022]
Abstract
Severe respiratory distress syndrome (RDS) is still a major cause of mortality and morbidity in premature infants. The combined use of intratracheal corticosteroid and surfactant in severe RDS, which bypasses the systemic circulation, may not only help recruit the lungs but also alleviates pulmonary inflammation without an increase in systemic adverse effects. Twelve newborn piglets received repeated pulmonary saline lavage to create surfactant-depleted lungs that mimic neonatal RDS, and then were randomly grouped into a control group (standard intratracheal instillation of surfactant-Survanta 100 mg/kg); and a budesonide (Bude) group (intratracheal instillation with the mixed suspension of Budesonide 0.25 mg/kg and Survanta 100 mg/kg). Blood samples were examined, and the observation period was 24 hr. The results showed that oxygenation was significantly better in Bude group compared to the control group over time (P = 0.016). The proinflammatory cytokines tumor necrosis factor-α and interleukin-1 β showed a reduced trend in the Bude group, but was not significantly different from the control group (P > 0.05). Comparing the histological lung injury scores, the Bude group had a significantly lower score than the control group at both dependent and non-dependent sites (P < 0.05). In conclusion, in piglets with severe RDS, intratracheal instillation of budesonide in addition to surfactant seems to results in a sustained improvement in pulmonary outcome over 24 hr.
Collapse
Affiliation(s)
- Chia-Feng Yang
- Institute of Emergency and Critical Care Medicine, and Department of Pediatrics, School of Medicine, National Yang-Ming University, Taipei, Taiwan
| | | | | | | | | | | | | | | |
Collapse
|